Avalo Therapeutics Files 8-K on Officer/Director Changes
Ticker: AVTX · Form: 8-K · Filed: Sep 22, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Sep 22, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $2.6 billion, $6.7 billion, $1.1 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, governance, filing
Related Tickers: AVLO
TL;DR
AVLO 8-K: Leadership shakeup, director elections, and officer appointments reported as of Sept 16.
AI Summary
Avalo Therapeutics, Inc. filed an 8-K on September 22, 2025, reporting events as of September 16, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially when combined with financial statements, can signal underlying business challenges or strategic realignments that may affect the company's future performance.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Cerecor Inc. (company) — Former company name
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated September 16, 2025.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed on September 22, 2025.
What is Avalo Therapeutics, Inc.'s former company name?
Avalo Therapeutics, Inc.'s former company name was Cerecor Inc.
What are the key items covered in this 8-K filing?
The key items covered are the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and financial statements and exhibits.
Filing Stats: 1,123 words · 4 min read · ~4 pages · Grade level 10.5 · Accepted 2025-09-22 07:01:39
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
- $2.6 billion — by H. Lundbeck A/S in December 2024 for $2.6 billion. Prior to co-founding Longboard Pharmac
- $6.7 billion — Pharmaceuticals (acquired by Pfizer for $6.7 billion in 2022) from 2016 to 2020. During his
- $1.1 billion — anizations, he successfully raised over $1.1 billion in equity capital, secured valuable bus
Filing Documents
- avtx-20250916.htm (8-K) — 34KB
- ex-991bodappointment_sept2.htm (EX-99.1) — 13KB
- avalologoa.jpg (GRAPHIC) — 8KB
- 0001534120-25-000005.txt ( ) — 203KB
- avtx-20250916.xsd (EX-101.SCH) — 2KB
- avtx-20250916_def.xml (EX-101.DEF) — 14KB
- avtx-20250916_lab.xml (EX-101.LAB) — 24KB
- avtx-20250916_pre.xml (EX-101.PRE) — 15KB
- avtx-20250916_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press Release dated September 22 , 2025 . 104 The cover pages of this Current Report on Form 8-K, formatted in Inline XBRL. 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: September 22, 2025 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 3